Accrued Expenses and Restructuring Reserve (Tables)

3 Months Ended

Mar. 31, 2019

Accrued Expenses and Restructuring Reserve [Abstract]

Accrued expenses and other liabilities consist of the following:

	As of March 31, 2019		As of December 31, 2018
Accrued research and development costs	$	172,190	$	71,329
Accrued professional fees		221,528		421,617
Accrued compensation		45,244		54,269
Accrued other		–		46,674
Accrued rent		8,000		8,000
Total	$	446,962	$	601,889

Restructuring Reserve

	As of March 31, 2019		As of December 31, 2018
Restructuring reserve (1)	$	1,948,596	$	–
Total	$	1,948,596	$	–

(1)

Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. For the three months ended March 31, 2019, the Company incurred $121,675 of restructuring expense which is recognized within general and administrative expense.